Moomoo AI 已提取核心信息
Eli Lilly and Company (LLY.US), a leading pharmaceutical company, has announced the issuance of a series of new notes under a preliminary prospectus supplement dated February 7, 2024. The offering includes multiple tranches of notes with varying maturity dates and interest rates, payable semi-annually. The notes, unsecured and unsubordinated debt obligations, will rank equally with other unsecured indebtedness of the company. The aggregate principal amount, interest rates, maturity dates, and other specific terms of the notes will be determined at the time of sale. The notes are being offered through a group of joint book-running managers, including BofA Securities, Barclays, Citigroup, Deutsche Bank Securities, and Mizuho. The proceeds from the sale of the notes are intended for general corporate purposes, which may include debt repayment and refinancing. The notes will not be listed on any securities exchange, and the underwriters expect to deliver them to investors in book-entry form through The Depository Trust Company on or about a specified date in 2024.
Eli Lilly and Company (LLY.US), a leading pharmaceutical company, has announced the issuance of a series of new notes under a preliminary prospectus supplement dated February 7, 2024. The offering includes multiple tranches of notes with varying maturity dates and interest rates, payable semi-annually. The notes, unsecured and unsubordinated debt obligations, will rank equally with other unsecured indebtedness of the company. The aggregate principal amount, interest rates, maturity dates, and other specific terms of the notes will be determined at the time of sale. The notes are being offered through a group of joint book-running managers, including BofA Securities, Barclays, Citigroup, Deutsche Bank Securities, and Mizuho. The proceeds from the sale of the notes are intended for general corporate purposes, which may include debt repayment and refinancing. The notes will not be listed on any securities exchange, and the underwriters expect to deliver them to investors in book-entry form through The Depository Trust Company on or about a specified date in 2024.
领先的制药公司礼来公司（LLY.US）宣布根据2024年2月7日的初步招股说明书补充文件发行一系列新票据。本次发行包括多批到期日和利率不同的票据，每半年支付一次。这些票据，包括无抵押和非次级债务，将与公司的其他无抵押债务同等地位。票据的本金总额、利率、到期日和其他具体条款将在出售时确定。这些票据由包括美银证券、巴克莱、花旗集团、德意志银行证券和瑞穗在内的多家联席账簿管理公司发行。出售票据的收益用于一般公司用途，其中可能包括债务偿还和再融资。这些票据不会在任何证券交易所上市，承销商预计将在2024年的指定日期或前后通过存托信托公司以账面记账形式将其交付给投资者。
领先的制药公司礼来公司（LLY.US）宣布根据2024年2月7日的初步招股说明书补充文件发行一系列新票据。本次发行包括多批到期日和利率不同的票据，每半年支付一次。这些票据，包括无抵押和非次级债务，将与公司的其他无抵押债务同等地位。票据的本金总额、利率、到期日和其他具体条款将在出售时确定。这些票据由包括美银证券、巴克莱、花旗集团、德意志银行证券和瑞穗在内的多家联席账簿管理公司发行。出售票据的收益用于一般公司用途，其中可能包括债务偿还和再融资。这些票据不会在任何证券交易所上市，承销商预计将在2024年的指定日期或前后通过存托信托公司以账面记账形式将其交付给投资者。
有用
没用